Published in Addiction on February 09, 2010
Commentary on Salmon et al. (2010): The case for safer inhalation facilities--waiting to inhale. Addiction (2010) 0.76
Risk environments facing potential users of a supervised injection site in Ottawa, Canada. Harm Reduct J (2015) 0.76
Willingness to access an in-hospital supervised injection facility among hospitalized people who use illicit drugs. J Hosp Med (2015) 0.75
Evaluating the impact of a national naloxone programme on ambulance attendance at overdose incidents: a controlled time-series analysis. Addiction (2016) 0.75
Willingness to use a supervised injection facility among young adults who use prescription opioids non-medically: a cross-sectional study. Harm Reduct J (2017) 0.75
Acceptability and design preferences of supervised injection services among people who inject drugs in a mid-sized Canadian City. Harm Reduct J (2017) 0.75
Public Health and Public Order Outcomes Associated with Supervised Drug Consumption Facilities: a Systematic Review. Curr HIV/AIDS Rep (2017) 0.75
Reemergence of the HIV epidemic among men who have sex with men in North America, Western Europe, and Australia, 1996-2005. Ann Epidemiol (2009) 4.36
Ethical challenges and responses in harm reduction research: promoting applied communitarian ethics. Drug Alcohol Rev (2005) 4.02
Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial. Clin Infect Dis (2009) 3.32
Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population. AIDS (2013) 3.30
The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology (2013) 3.14
How good is "good enough"? The case for varying standards of evidence according to need for new interventions in HIV prevention. Am J Bioeth (2012) 2.93
Modelling hepatitis C virus incidence, prevalence and long-term sequelae in Australia, 2001. Int J Epidemiol (2003) 2.65
Beyond detuning: 10 years of progress and new challenges in the development and application of assays for HIV incidence estimation. AIDS (2010) 2.43
How effective are short message service reminders at increasing clinic attendance? A meta-analysis and systematic review. Health Serv Res (2011) 2.42
Sex, race, and geographic region influence clinical outcomes following primary HIV-1 infection. J Infect Dis (2011) 2.34
Four-year follow-up of imprisoned male heroin users and methadone treatment: mortality, re-incarceration and hepatitis C infection. Addiction (2005) 2.24
Sequential bottlenecks drive viral evolution in early acute hepatitis C virus infection. PLoS Pathog (2011) 2.13
Undetectable viral load is associated with sexual risk taking in HIV serodiscordant gay couples in Sydney. AIDS (2005) 2.10
A double-blind, placebo-controlled trial of modafinil (200 mg/day) for methamphetamine dependence. Addiction (2009) 2.03
Effective treatment of injecting drug users with recently acquired hepatitis C virus infection. Gastroenterology (2009) 1.99
Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. JAMA (2002) 1.88
Changes over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks. Int J Epidemiol (2002) 1.79
Immunopathogenesis and diagnosis of tuberculosis and tuberculosis-associated immune reconstitution inflammatory syndrome during early antiretroviral therapy. J Infect Dis (2009) 1.79
Young women engaged in sex work in Phnom Penh, Cambodia, have high incidence of HIV and sexually transmitted infections, and amphetamine-type stimulant use: new challenges to HIV prevention and risk. Sex Transm Dis (2011) 1.74
Cohort profile: the TREAT Asia pediatric HIV observational database. Int J Epidemiol (2010) 1.70
Use of viral load to negotiate condom use among gay men in Sydney, Australia. AIDS Behav (2009) 1.62
Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS (2004) 1.61
Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study. Lancet Infect Dis (2015) 1.61
Trends in agreements between regular partners among gay men in Sydney, Melbourne and Brisbane, Australia. AIDS Behav (2008) 1.60
'It's more about the heroin': injection drug users' response to an overdose warning campaign in a Canadian setting. Addiction (2013) 1.56
Botulinum injection for the management of myofascial pain in the masticatory muscles. A prospective outcome study. Br J Oral Maxillofac Surg (2012) 1.55
A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand. Hepatology (2008) 1.52
Sun exposure may protect against non-Hodgkin lymphoma: a case-control study. Int J Cancer (2004) 1.50
The pattern of excess cancer in dialysis and transplantation. Nephrol Dial Transplant (2009) 1.48
Mortality rates among nuclear industry workers at Lucas Heights Science and Technology Centre. Aust N Z J Public Health (2005) 1.45
Changes in hematologic parameters and efficacy of thymidine analogue-based, highly active antiretroviral therapy: a meta-analysis of six prospective, randomized, comparative studies. Clin Ther (2004) 1.43
Cohort profile: the international collaboration of incident HIV and hepatitis C in injecting cohorts (InC3) study. Int J Epidemiol (2012) 1.39
Efficacy of interventions to increase the uptake of chlamydia screening in primary care: a systematic review. BMC Infect Dis (2011) 1.34
Pilot randomized double blind placebo-controlled study of dexamphetamine for cocaine dependence. Addiction (2003) 1.32
Integrated HIV DNA accumulates prior to treatment while episomal HIV DNA records ongoing transmission afterwards. AIDS (2012) 1.29
The 2004 Australian prison entrants' blood-borne virus and risk behaviour survey. Aust N Z J Public Health (2007) 1.29
Foreskin cutting beliefs and practices and the acceptability of male circumcision for HIV prevention in Papua New Guinea. BMC Public Health (2013) 1.25
Activation of NK cells by ADCC antibodies and HIV disease progression. J Acquir Immune Defic Syndr (2011) 1.24
Risk factors for HIV seroconversion in homosexual men in Australia. Sex Health (2006) 1.24
Measurement of serum levels of macrophage inhibitory cytokine 1 combined with prostate-specific antigen improves prostate cancer diagnosis. Clin Cancer Res (2006) 1.23
Immunosuppression and other risk factors for early and late non-Hodgkin lymphoma after kidney transplantation. Blood (2009) 1.23
Immunodeficiency and the risk of serious clinical endpoints in a well studied cohort of treated HIV-infected patients. AIDS (2010) 1.23
Correlates of amphetamine-type stimulant use and associations with HIV-related risks among young women engaged in sex work in Phnom Penh, Cambodia. Drug Alcohol Depend (2011) 1.21
The role of diet and other environmental factors in the causation of gastric cancer in Iran--a population based study. Int J Cancer (2009) 1.21
Quantifying the dose-response of walking in reducing coronary heart disease risk: meta-analysis. Eur J Epidemiol (2009) 1.21
Specific antibody-dependent cellular cytotoxicity responses associated with slow progression of HIV infection. Immunology (2013) 1.19
How has the sexual behaviour of gay men changed since the onset of AIDS: 1986-2003. Aust N Z J Public Health (2005) 1.19
Injection drug use and hepatitis C virus infection in young adult injectors: using evidence to inform comprehensive prevention. Clin Infect Dis (2013) 1.19
Effect of reduced immunosuppression after kidney transplant failure on risk of cancer: population based retrospective cohort study. BMJ (2010) 1.18
How can hepatitis C be prevented in the long term? Int J Drug Policy (2007) 1.18
Sex work and HIV in Cambodia: trajectories of risk and disease in two cohorts of high-risk young women in Phnom Penh, Cambodia. BMJ Open (2013) 1.18
Incidence of primary hepatitis C infection and risk factors for transmission in an Australian prisoner cohort. BMC Public Health (2010) 1.18
Incidence and risk for acute hepatitis C infection during imprisonment in Australia. Eur J Epidemiol (2010) 1.18
A typology of penile cutting in Papua New Guinea: results of a modified Delphi study among sexual health specialists. AIDS Care (2011) 1.16
Risk of non-Hodgkin lymphoma associated with occupational exposure to solvents, metals, organic dusts and PCBs (Australia). Cancer Causes Control (2005) 1.16
Prevalence of production of virus-specific interferon-gamma among seronegative hepatitis C-resistant subjects reporting injection drug use. J Infect Dis (2004) 1.14
Changes in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudine. PLoS One (2012) 1.14
Cervical human papillomavirus infection among young women engaged in sex work in Phnom Penh, Cambodia: prevalence, genotypes, risk factors and association with HIV infection. BMC Infect Dis (2012) 1.13
Characterizing trends in HIV infection among men who have sex with men in Australia by birth cohorts: results from a modified back-projection method. J Int AIDS Soc (2009) 1.13
Estimating the cost-effectiveness of needle-syringe programs in Australia. AIDS (2012) 1.11
Serum macrophage inhibitory cytokine-1 (MIC-1/GDF15): a potential screening tool for the prevention of colon cancer? Cancer Epidemiol Biomarkers Prev (2011) 1.11
Further evidence of HCV sexual transmission among HIV-positive men who have sex with men: response to Danta et al. AIDS (2007) 1.11
Estimating population attributable risk for hepatitis C seroconversion in injecting drug users in Australia: implications for prevention policy and planning. Addiction (2009) 1.10
Injection drug users' involvement in drug dealing in the downtown eastside of Vancouver: social organization and systemic violence. Int J Drug Policy (2013) 1.09
Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 Infection: the OzCombo 2 study. HIV Clin Trials (2002) 1.09
Frequent occurrence of undiagnosed pelvic inflammatory disease in remote communities of central Australia. Med J Aust (2012) 1.08
Modelling the hepatitis C virus epidemic in Australia. Drug Alcohol Depend (2007) 1.08
Australia's notifiable diseases status, 2001: annual report of the National Notifiable Diseases Surveillance System. Commun Dis Intell Q Rep (2003) 1.07
Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection. Hepatology (2012) 1.07
Efficacy and tolerability of initial antiretroviral therapy: a systematic review. AIDS (2009) 1.07
Predictors of frequent use of amphetamine type stimulants among HIV-negative gay men in Sydney, Australia. Drug Alcohol Depend (2007) 1.06
Abacavir does not affect circulating levels of inflammatory or coagulopathic biomarkers in suppressed HIV: a randomized clinical trial. AIDS (2010) 1.06
Pigmentary characteristics, sun sensitivity and non-Hodgkin lymphoma. Int J Cancer (2004) 1.05
Prevalence of sexually transmitted infections among antenatal women in Vanuatu, 1999-2000. Sex Transm Dis (2003) 1.05
Cutaneous melanoma is related to immune suppression in kidney transplant recipients. Cancer Epidemiol Biomarkers Prev (2009) 1.05
Intensification of antiretroviral therapy with raltegravir or addition of hyperimmune bovine colostrum in HIV-infected patients with suboptimal CD4+ T-cell response: a randomized controlled trial. J Infect Dis (2011) 1.05
The reliability of sensitive information provided by injecting drug users in a clinical setting: clinician-administered versus audio computer-assisted self-interviewing (ACASI). AIDS Care (2012) 1.05
Lack of correlation between three commercial platforms for the evaluation of human immunodeficiency virus type 1 (HIV-1) viral load at the clinically critical lower limit of quantification. J Clin Virol (2010) 1.04
Clearance of hepatitis C virus after newly acquired infection in injection drug users. J Infect Dis (2004) 1.04
Early proliferation of CCR5(+) CD38(+++) antigen-specific CD4(+) Th1 effector cells during primary HIV-1 infection. Blood (2005) 1.04
The impact of needle and syringe programs on HIV and HCV transmissions in injecting drug users in Australia: a model-based analysis. J Acquir Immune Defic Syndr (2009) 1.04
A randomized, double-blind study of gemfibrozil for the treatment of protease inhibitor-associated hypertriglyceridaemia. AIDS (2002) 1.01
Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy. J Antimicrob Chemother (2005) 1.00
Some characteristics of early-onset injection drug users prior to and at the time of their first injection. Addiction (2006) 0.99
A prospective study of hepatitis C incidence in Australian prisoners. Addiction (2014) 0.99
Extending drug ethno-epidemiology using agent-based modelling. Addiction (2009) 0.98
Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users. J Hepatol (2010) 0.98